Topical Ketoprofen 10% Cream — Competitive Intelligence Brief

Topical Ketoprofen 10% Cream (Topical Ketoprofen 10% Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID (nonsteroidal anti-inflammatory drug). Area: Pain Management / Rheumatology.

phase 3 NSAID (nonsteroidal anti-inflammatory drug) COX-1, COX-2 Pain Management / Rheumatology Small molecule

Target snapshot

Topical Ketoprofen 10% Cream (Topical Ketoprofen 10% Cream) — Imprimis Pharmaceuticals, Inc.. Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Topical Ketoprofen 10% Cream TARGET	Topical Ketoprofen 10% Cream	Imprimis Pharmaceuticals, Inc.	phase 3	NSAID (nonsteroidal anti-inflammatory drug)	COX-1, COX-2
Standard Dose Ibuprofen	Standard Dose Ibuprofen	Ottawa Hospital Research Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Codeine paracetamol	Codeine paracetamol	Napp Pharmaceuticals Limited	marketed	Opioid analgesic combination	Opioid receptors (μ, δ, κ); cyclooxygenase (COX-1, COX-2)
Pranoprofen eye drops	Pranoprofen eye drops	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1, COX-2)
optimized ibuprofen	optimized ibuprofen	OSF Healthcare System	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
EC Aspirin 325	EC Aspirin 325	POZEN	marketed	Antiplatelet agent / NSAID	Cyclooxygenase (COX-1, COX-2)
Ibuprofen 2%	Ibuprofen 2%	Berlin-Chemie AG Menarini Group	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID (nonsteroidal anti-inflammatory drug) class)

1. Depomed · 1 drug in this class
2. Dong-A ST Co., Ltd. · 1 drug in this class
3. Handok Inc. · 1 drug in this class
4. Imprimis Pharmaceuticals, Inc. · 1 drug in this class
5. Kunming Baker Norton Pharmaceutical Sales Co., Ltd. · 1 drug in this class
6. LEO Pharma · 1 drug in this class
7. Novartis · 1 drug in this class
8. Pfizer · 1 drug in this class
9. University of South Alabama · 1 drug in this class
10. ZARS Pharma Inc. · 1 drug in this class